SPY334.25-1.32 -0.39%
DIA278.34+0.20 0.07%
IXIC10,847.70-120.66 -1.10%

Aravive, AstraZeneca Report Initiation Of Randomized Phase 1/2 Study Of AVB-500 In Combo With Durvalumab In Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

Benzinga · -